An older man sits with assurance on a throne of musical instruments while he grasps a trumpet.An older man sits with assurance on a throne of diverse musical instruments, grasping a trumpet.

THE ONLY NOVEL*
ANDROGEN INHIBITORWITH 240 MG, SINGLE-TABLET,ONCE-DAILY DOSING1-3*ERLEADA® is a second-generation androgen receptor inhibitor.4

ERLEADA® OFFERS MORE FLEXIBILITY FOR YOUR PATIENTS1

ONE 240 MG TABLET OR FOUR 60 MG TABLETS—ADMINISTERED ORALLY ONCE DAILY†

60 mg tablet
4 tablets, once daily

60mg_cropped.png

(~17 mm x 9 mm)

240 mg tablet
1 tablet, once daily

240mg-cropped.png

(~21 mm x 10 mm)

Size comparison of 60 mg
and 240 mg tablets

tablet_comparison.png

Tablets shown are not actual size.5

†Patients receiving ERLEADA® should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

  • Provides alternate methods of administration for patients who have difficulty swallowing tablets whole or have a feeding tube
  • Does not require concurrent chemotherapy

†Patients receiving ERLEADA® should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

erleada_dosing_icon_a1.svg

No initial dose adjustments needed for renal or hepatic impairment1‡

‡ERLEADA® has not been evaluated in
patients with severe renal or hepatic impairment.

concurrent_therapy_bin_icon.svg

No need for concurrent chemotherapy1

erleada_dosing_icon_a3.svg

Do not crush or split tablet(s). ERLEADA® can be taken with or without food§

§For alternate methods of administration, tablets may be dispersed according to the instructions for alternate dosing methods.

DOSAGE MODIFICATION

If Grade 3 or greater adverse reactions or other intolerable adverse reactions occur, withhold ERLEADA®. Consider permanent discontinuation of ERLEADA® for Grade 3 or 4 cerebrovascular and ischemic cardiovascular events. Permanently discontinue ERLEADA® for severe ILD/pneumonitis or if no other potential causes of ILD/pneumonitis are identified, or confirmed SCARs or for other Grade 4 skin reactions. For other adverse reactions, when symptoms improve to ≤Grade 1 or original grade, resume ERLEADA® at the same dose or a reduced dose (180 mg or 120 mg), if warranted.1

For detailed instructions on administration, please see the full ERLEADA® Prescribing Information.

ERLEADA® IS THE ONLY NOVEL ANDROGEN RECEPTOR INHIBITOR WITH 240 MG, SINGLE-TABLET, ONCE-DAILY DOSING1-3

FDA-approved androgen receptor inhibitors|| for the treatment of mCSPC1-3¶

comparison_bannercomparison_banner

||Patients receiving these ARI therapies should also receive a GnRH analog concurrently or should have had bilateral orchiectomy.

Product comparisons with regard to efficacy and safety cannot be made in the absence of head-to-head clinical studies. This presentation is not intended to compare the relative efficacy or safety of the treatments. Please refer to the full Prescribing Information of each agent for dosage and administration.

#For detailed instructions on administration, please see the full ERLEADA® Prescribing Information.

THE ONLY ANDROGEN RECEPTOR INHIBITOR WITH THE CONVENIENCE OF ALTERNATE METHODS OF ADMINISTRATION1-3

ERLEADA® offers the convenience of alternate methods of administration for patients who have difficulty swallowing tablets whole or who have a feeding tube1**

ERLEADA® Alternate Methods of Administration

orange_juiceicon.png

Orange juice

apple_sauceicon.png

Applesauce

water_icon.png

Noncarbonated water

feeding_tubeicon.png

Or through feeding tube

**For detailed instructions on administration, please see the full ERLEADA® Prescribing Information.

alternate_instruction_icon.png

Instructions for alternate dosing methods

Download

alternate_instruction_icon.png

Starting and Staying on ERLEADA® Guide

Download

ARI = androgen receptor inhibitor; BID = twice a day; GnRH = gonadotropin-releasing hormone; mCSPC = metastatic castration-sensitive prostate cancer; QD = once a day; SCARs = severe cutaneous adverse reactions.

REFERENCES:

  1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Nubeqa® [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.
  3. Xtandi® [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 17, 2024. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  5. Data on file. Janssen Biotech, Inc.